-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Benzinga·10/13/2026 11:48:29
Listen to the news
Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.